Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H20FN3O3.CH4O3S.2H2O |
| Molecular Weight | 465.494 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.CS(O)(=O)=O.CCN1C=C(C(O)=O)C(=O)C2=C1C=C(N3CCN(C)CC3)C(F)=C2
InChI
InChIKey=LEULAXMUNMRLPW-UHFFFAOYSA-N
InChI=1S/C17H20FN3O3.CH4O3S.2H2O/c1-3-20-10-12(17(23)24)16(22)11-8-13(18)15(9-14(11)20)21-6-4-19(2)5-7-21;1-5(2,3)4;;/h8-10H,3-7H2,1-2H3,(H,23,24);1H3,(H,2,3,4);2*1H2
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C17H20FN3O3 |
| Molecular Weight | 333.3574 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | CH4O3S |
| Molecular Weight | 96.106 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Pefloxacin is a fluorinated quinolone that is structurally related to nalidixic acid. It can be administered both orally and intravenously, and has a broad spectrum of in vitro activity against Gram-negative organisms and staphylococci. The bactericidal action of pefloxacin results from interference with the activity of the bacterial enzymes DNA gyrase and topoisomerase IV, which are needed for the transcription and replication of bacterial DNA. DNA gyrase appears to be the primary quinolone target for gram-negative bacteria. Topoisomerase IV appears to be the preferential target in gram-positive organisms. Interference with these two topoisomerases results in strand breakage of the bacterial chromosome, supercoiling, and resealing. As a result DNA replication and transcription is inhibited. It is prescribed for the treatment of uncomplicated gonococcal urethritis in males and for gram-negative bacterial infections in gastrointestinal system and genitourinary tract.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Isolation of E. coli from foam and effects of fluoroquinolones on E. coli and foam production in male Japanese quail. | 2004-11 |
|
| Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis. | 2004-10 |
|
| A three-way comparative study on the efficacy of twin sol to gel systems and marketed eye drops of pefloxacin mesylate. | 2004-08 |
|
| Some plasma and saliva pharmacokinetics parameters of rifampicin in the presence of pefloxacin. | 2004-07-22 |
|
| [Pharmacokinetics and dose adaptation of ofloxacine, pefloxacine and ciprofloxacine during haemodialysis and continuous ambulatory peritoneal dialysis]. | 2004-05 |
|
| Antimicrobial resistance in commensal flora of pig farmers. | 2004-05 |
|
| Mechanisms of pefloxacin-induced pain. | 2004-04 |
|
| Effects of acetyl salicylate and ibuprofen on fluoroquinolone MICs on Salmonella enterica serovar typhimurium in vitro. | 2004-04 |
|
| Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. | 2004-04 |
|
| Extension of the isobolographic approach to interactions studies between more than two drugs: illustration with the convulsant interaction between pefloxacin, norfloxacin, and theophylline in rats. | 2004-03 |
|
| Effect of pefloxacin on the urinary excretion of rifampicin. | 2004-01-06 |
|
| In vitro discrimination of fluoroquinolones toxicity on tendon cells: involvement of oxidative stress. | 2004-01 |
|
| Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. | 2004 |
|
| [Antibiotherapy in osteoarticular infections in children suffering from hemoglobinopathy in the University Teaching Hospital of Yopougon]. | 2003-12-25 |
|
| X-ray powder diffraction patterns for certain fluoroquinolone antibiotic drugs. | 2003-12 |
|
| Activity of combinations of ceftazidime, imipenem and pefloxacin against Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. | 2003-12 |
|
| Dose ranging pharmacokinetics and brain distribution of norfloxacin using microdialysis in rats. | 2003-12 |
|
| Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients. | 2003-11-15 |
|
| [Enterobacterial susceptibility to antibiotics in northern Lebanon (1998-2001)]. | 2003-10-08 |
|
| Comparative in-vitro activities of commonly available quinolones and other antibiotics on bacterial isolates in Ibadan, Nigeria. | 2003-09-27 |
|
| [Drug sensitivity of Ureaplasma urealyticum, persisting in patients with chronic inflammatory diseases of the urogenital tract]. | 2003-09-12 |
|
| [Experience in using the new drug moxifloxacin (Avelox, "Bayer", Germaniia) in urologic practice]. | 2003-07-09 |
|
| Fluoroquinolone-associated tendinopathy: a critical review of the literature. | 2003-06-01 |
|
| Staphylococcus aureus carriage in selected communities and their antibiotic susceptibility patterns. | 2003-06 |
|
| Antimicrobial sensitivity pattern of organisms causing urinary tract infection in children with sickle cell anaemia in Ibadan, Nigeria. | 2003-06 |
|
| Molecular epidemiology of ampicillin-resistant clinical isolates of Salmonella enterica serovar Typhimurium. | 2003-06 |
|
| Pharmacokinetics and tissue penetration of pefloxacin plus metronidazole after administration as surgical prophylaxis in colorectal surgery. | 2003-06 |
|
| Determination of the antibiotic drug pefloxacin in bulk form, tablets and human serum using square wave cathodic adsorptive stripping voltammetry. | 2003-04-10 |
|
| Microbial isolates in open fractures seen in the accident and emergency unit of a teaching hospital in a developing country. | 2003-04-01 |
|
| [Study of filter-paper-substrate delay fluorescence of three quinolones]. | 2003-04 |
|
| The effect of nitric oxide combined with fluoroquinolones against Salmonella enterica serovar Typhimurium in vitro. | 2003-04 |
|
| A microarray-based antibiotic screen identifies a regulatory role for supercoiling in the osmotic stress response of Escherichia coli. | 2003-02 |
|
| Activities of 13 quinolones by three susceptibility testing methods against a collection of Haemophilus influenzae isolates with different levels of susceptibility to ciprofloxacin: evidence for cross-resistance. | 2003-01 |
|
| [Formation of virulent antigen-modified mutants (Fra-, Fra-Tox-) of plague bacteria resistant to rifampicin and quinolones]. | 2003 |
|
| Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three italian regions. | 2003 |
|
| In vitro antimicrobial interactions of arthemeter with some 4-quinolones. | 2002-12-17 |
|
| Antibiotic sensitivity and resistance profile of the micro-organisms responsible for urinary tract infection observed in Kashmir, India. | 2002-11 |
|
| [Tenotoxic potential of fluoroquinolones in the choice of surgical antibiotic prophylaxis in ophthalmology]. | 2002-11 |
|
| [Diagnosis and treatment of legionella pneumonia]. | 2002-11 |
|
| Some pharmacokinetic parameters of pefloxacin in lactating goats. | 2002-10 |
|
| Pharmacokinetics and tissue distribution of intravenous pefloxacin for antibiotic prophylaxis in biliary surgery. | 2002-10 |
|
| [Bacteriologic examination of gallbladder contents]. | 2002-08-13 |
|
| [Pefloxacin (Abaktal)--efficacy in treating severe infections, optimization of treatment based on pharmacokinetic and pharmacodynamic parameters]. | 2002 |
|
| [Efficacy of some new antibiotics in treating experimental brucellosis]. | 2002 |
|
| [On fluoroquinolones treatment safety in children (clinical, morphological and catamnesis data)]. | 2002 |
|
| [Pefloxacin in the treatment of patients with mucoviscidosis]. | 2002 |
|
| Clinical role of protein binding of quinolones. | 2002 |
|
| [Neurologic side effects of fluoroquinolones. Apropos of 9 cases concerning pefloxacin]. | 1992-09-01 |
|
| Peripheral neuropathy associated with fluoroquinolones. | 1992-07-11 |
|
| Non-nephrotoxic empiric antimicrobial therapy in febrile neutropenic cancer patients. | 1992 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:25:54 GMT 2025
by
admin
on
Mon Mar 31 19:25:54 GMT 2025
|
| Record UNII |
CX28QC6FU0
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6917670
Created by
admin on Mon Mar 31 19:25:54 GMT 2025 , Edited by admin on Mon Mar 31 19:25:54 GMT 2025
|
PRIMARY | |||
|
CX28QC6FU0
Created by
admin on Mon Mar 31 19:25:54 GMT 2025 , Edited by admin on Mon Mar 31 19:25:54 GMT 2025
|
PRIMARY | |||
|
m8442
Created by
admin on Mon Mar 31 19:25:54 GMT 2025 , Edited by admin on Mon Mar 31 19:25:54 GMT 2025
|
PRIMARY | Merck Index | ||
|
149676-40-4
Created by
admin on Mon Mar 31 19:25:54 GMT 2025 , Edited by admin on Mon Mar 31 19:25:54 GMT 2025
|
PRIMARY | |||
|
SUB12199MIG
Created by
admin on Mon Mar 31 19:25:54 GMT 2025 , Edited by admin on Mon Mar 31 19:25:54 GMT 2025
|
PRIMARY | |||
|
DBSALT000852
Created by
admin on Mon Mar 31 19:25:54 GMT 2025 , Edited by admin on Mon Mar 31 19:25:54 GMT 2025
|
PRIMARY | |||
|
100000079621
Created by
admin on Mon Mar 31 19:25:54 GMT 2025 , Edited by admin on Mon Mar 31 19:25:54 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ANHYDROUS->SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |